// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

GI restricted ROCK inhibitors show potential to treat fibrosis and stenosis associated with inflammatory bowel disease

C Jones - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

N/A

A distinct cellular signature of inflammatory bowel disease

E McDonald - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Human neutrophil elastase degrades the therapeutic monoclonal antibodies effective in IBD

K Kok - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Entyvio

MRI T2 relaxometry-based measures of intestinal inflammation in a human intestinal permeability model: a pilot study

R Scott - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Indomethacin

Proliferating intestinal macrophage populations in human inflammatory bowel disease

E McDonald - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Anatomical brain changes in active Crohn’s disease patients

G Thapaliya - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Basement membrane remodelling as a biomarker for monitoring disease activity in Crohn’s disease patients: the role of laminin

M L Olesen - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

dextran sulfate sodium

Epithelial to mesenchymal transition is a hallmark of fibrostenosing Crohn’s disease and is associated with down regulation of the miR-200 family

S J Mehta - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Host–microbial crosstalk in the pathogenesis of colon cancer in Primary sclerosing cholangitis

M Neyazi - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Paediatric Crohn’s disease patients in remission have a reduced skeletal muscle protein balance after feeding

A Walker - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Bacterial handling defect in macrophages of patients with defects in glucose-6-phosphate metabolism and Crohn’s disease like intestinal inflammation

S Pandey - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Gentamicin

Th17 cells dominate the colonic mucosal immune response in primary sclerosing cholangitis associated colitis

M N Quraishi - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Intestinal expression of LAG-3 correlates with inflammatory activity and response to biological therapy in ulcerative colitis

S Slevin - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Characterising and managing issues with food-related quality of life in inflammatory bowel disease: a qualitative study of patients and healthcare professionals

W Czuber-Dochan - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

An investigation of taste preference to oral nutritional supplement drinks (ONS) in adolescent and adult Crohn’s disease (CD) and attitudes towards their long-term use

K Keetarut - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Upper GI endoscopy is an expensive accessory investigation in the diagnosis of Crohn’s disease in children

R Al-Araji - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Evaluation of the clinical course of Adolescent inflammatory bowel disease patients at Nottingham University Hospital

D -c Osei-Bordom - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Serological assessment of type XVI collagen reflects intestinal strictures in Crohn’s disease patients

J H Mortensen - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Long-term outcomes after anti-TNF therapy withdrawal in patients with radiologically healed perianal Crohn’s fistulas

W Y Mak - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Intra-abdominal sepsis following ileocolic resection for Crohn’s disease: What are the risk factors and are they consistent internationally?

A Lightner - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved